Pierre Besson

Dr. Pierre Besson

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
VDVirginie Driffort
Virginie Driffort
LGLudovic Gillet
Ludovic Gillet
EBEmeline Bon
Emeline Bon
SLSéverine Lambot
Séverine Lambot
TOThibauld Oullier
Thibauld Oullier
Sebastien RogerSebastien Roger
Sebastien Roger
NaV1.5 voltage-gated sodium channels are abnormally expressed in breast tumours and their expression level is associated with metastatic occurrence and patients' death. In breast cancer cells, NaV1.5 activity promotes the proteolytic degradation of the extracellular matrix and enhances cell invasiveness.

29 July 2015 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SRSã©Bastien Roger
Sã©Bastien Roger
LGLudovic Gillet
Ludovic Gillet
JGJean-Yves Le Guennec
Jean-Yves Le Guennec
PBPierre Besson
Pierre Besson
Voltage-gated sodium channels (NaV) are molecular characteristics of excitable cells. Their activation, triggered by membrane depolarization, generates transient sodium currents that initiate action potentials in neurons and muscle cells. Sodium currents were discovered by A. Hodgkin and A. Huxley using the voltage clamp technique and reported in their landmark series of papers in 1952. It was only in the 1980's that sodium channel proteins from excitable membranes were molecularly characterized by W. Catterall and his collaborators. Non-excitable cells can also express NaV channels in physiological conditions as well as in pathological conditions. These NaV channels can sustain biological roles that are not related to the generation of action potentials. Interestingly, it is likely that the abnormal expression of Na¬V in pathological tissues can reflect the re-expression of a fetal phenotype. This is especially true in epithelial cancer cells for which these channels have been identified and sodium currents recorded, while it was not the case for cells from the cognate normal tissues. In cancers, the functional activity of NaV appeared to be involved in regulating the proliferative, migrative and invasive properties of cells. This review is aimed at addressing the non-excitable roles of NaV channels with a specific emphasis in the regulation of cancer cell biology.

1 October 2015 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
PBPierre Besson
Pierre Besson
VDVirginie Driffort
Virginie Driffort
ÉBÉmeline Bon
Émeline Bon
FGFrédéric Gradek
Frédéric Gradek
SCStephan Chevalier
Stephan Chevalier
Sebastien RogerSebastien Roger
Sebastien Roger

21 December 2015 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Jérôme RoyJérôme Roy
Jérôme Roy
LOLiliam Teixeira Oliveira
Liliam Teixeira Oliveira
COCamille Oger
Camille Oger
JGJean-Marie Galano
Jean-Marie Galano
VBValerie Bultel-Poncé
Valerie Bultel-Poncé
JGJean-Yves Le Guennec
Jean-Yves Le Guennec
Nanocapsules, as a delivery system, are able to target drugs and other biologically sensitive molecules to specific cells or organs. This system has been intensively investigated as a way to protect bioactives drugs from inactivation upon interaction with the body and to ensure the release to the target. However, the mechanism of improved activity of the nanoencapsulated molecules is far from being understood at the cellular and subcellular levels. Epidemiological studies suggest that dietary polyunsaturated fatty acids (PUFA) can reduce the morbidity and mortality from breast cancer. This influence could be modulated by the oxidative status of the diet and it has been suggested that the anti-proliferative properties of docosahexaenoic acid (DHA) are enhanced by pro-oxidant agents. The effect of encapsulation of PUFA on breast cancer cell proliferation in different oxidative medium was evaluated in vitro. We compared the proliferation of the human breast cancer cell line MDA-MB-231 and of the non-cancer human mammary epithelial cell line MCF-10A in different experimental conditions. DHA possessed anti-proliferative properties that were prevented by alpha-tocopherol (an antioxidant) and enhanced by the pro-oxidant hydrogen peroxide that confirms that DHA has to be oxidized to exert its anti-proliferative properties. We also evaluated the anti-proliferative effects of the 4(RS)-4-F4t-neuroprostane, a bioactive, non-enzymatic oxygenated metabolite of DHA known to play a major role in the prevention of cardiovascular diseases. DHA-loaded nanocapsules was less potent than non-encapsulated DHA while co-encapsulation of DHA with H2O2 maintained the inhibition of proliferation. The nanocapsules slightly improves the anti-proliferative effect in the case of 4(RS)-4-F4t-neuroprostane that is more hydrophilic than DHA. Overall, our findings suggest that the sensitivity of tumor cell lines to DHA involves oxidized metabolites. They also indicate that neuroprostane is a metabolite participating in the growth reducing effect of DHA, but it is not the sole. These results also suggest that NC seek to enhance the stability against degradation, enhance cellular availability, and control the release of bioactive fatty acids following their lipophilicities.

16 February 2010 in Biochimie
Verified
Journal Article
Closed access
LGLudovic Gillet
Ludovic Gillet
Sebastien RogerSebastien Roger
Sebastien Roger
PBPhilippe Bougnoux
Philippe Bougnoux
JGJean-Yves Le Guennec
Jean-Yves Le Guennec
PBPierre Besson
Pierre Besson

19 August 2020 in Cancers
Verified
Journal Article
Open access
PDF file
LBLucie Brisson
Lucie Brisson
SCStéphanie Chadet
Stéphanie Chadet
Osbaldo Lopez-CharcasOsbaldo Lopez-Charcas
Osbaldo Lopez-Charcas
BJBilel Jelassi
Bilel Jelassi
DTDavid Ternant
David Ternant
Sebastien RogerSebastien Roger
Sebastien Roger
The P2X7 receptor is an ATP-gated cation channel with a still ambiguous role in cancer progression, proposed to be either pro- or anti-cancerous, depending on the cancer or cell type in the tumour. Its role in mammary cancer progression is not yet defined. Here, we show that P2X7 receptor is functional in highly aggressive mammary cancer cells, and induces a change in cell morphology with fast F-actin reorganization and formation of filopodia, and promotes cancer cell invasiveness through both 2- and 3-dimensional extracellular matrices in vitro. Furthermore, P2X7 receptor sustains Cdc42 activity and the acquisition of a mesenchymal phenotype. In an immunocompetent mouse mammary cancer model, we reveal that the expression of P2X7 receptor in cancer cells, but not in the host mice, promotes tumour growth and metastasis development, which were reduced by treatment with specific P2X7 antagonists. Our results demonstrate that P2X7 receptor drives mammary tumour progression and represents a pertinent target for mammary cancer treatment.